-5%
Verivas is used to lower the risk of cardiovascular death and heart failure (HF) hospitalization in adults with symptomatic chronic heart failure and an ejection fraction below 45%, particularly after a recent HF hospitalization or a need for outpatient IV diuretics.
Vericiguat is a soluble guanylate cyclase (sGC) stimulator, a key enzyme in the nitric oxide (NO) signaling pathway.
- NO activates sGC, which increases production of cyclic guanosine monophosphate (cGMP).
- cGMP regulates vascular tone, heart muscle contractility, and cardiac remodeling.
- In heart failure, impaired NO production and reduced sGC activity worsen myocardial and vascular function.
By directly stimulating sGC—both independently and alongside NO—Vericiguat raises intracellular cGMP levels, promoting smooth muscle relaxation and vasodilation, ultimately improving cardiovascular performance.